A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-17. Anything still debated is marked as such rather than presented as settled.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Freeze-dried cake or loose powder after lyophilization |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are less durable than the powder |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light; avoid repeated freeze-thaw cycles |
| Identity method | Electrospray mass spectrometry | Compared against the expected mass; paired with sequence or composition analysis |
| Purity method | Reverse-phase HPLC with ultraviolet detection | Reports main-peak percentage rather than peptide content by mass |
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
=== Requirements === The Food and Nutrition Board of the U.S. Institute of Medicine set Recommended Dietary Allowances (RDAs) for essential amino acids in 2002. For methionine combined with cysteine, for adults 19 years and older, 19 mg/kg body weight/day. This translates to about 1.33 grams per day for a 70 kilogram individual.
== Exceptions == Peyote and ayahuasca, which contain mescaline and dimethyltryptamine (DMT), respectively, are exempt in certain spiritual or religious settings. A variety of notable psychedelics, including 4-AcO-DMT (psilacetin), 4-HO-MET, dipropyltryptamine (DPT), 5-MeO-MiPT, 5-MeO-AMT, 2C-EF, 2C-B-FLY, Bromo-DragonFLY, methallylescaline (MAL), ALD-52 (1A-LSD), 1P-LSD, ETH-LAD, and LSZ, among many others, are not explicitly controlled substances nor implicitly controlled isomers of scheduled psychedelics in the United States. However, these psychedelics and others could nonetheless be considered controlled substances if intended for human consumption under the Federal Analogue Act.
is unstable. Starting from almost everywhere in the concentration space, the system evolves to a homochiral state. It is generally understood that autocatalysis alone does not yield homochirality, and the presence of the mutually antagonistic relationship between the two enantiomers is necessary for the instability of the racemic mixture. Homochirality could be achieved from autocatalysis in the absence of the mutually antagonistic relationship, but the underlying mechanism for symmetry-breaking is different.
Sources: en.wikipedia.org
Growing evidence indicates that complete androgen receptor (AR) dysfunction disrupts systemic metabolic homeostasis and neither external nor endogenous estrogen can normalize it. AR absence is related to decrease in mature neutrophils in mice, but there is no evidence that human CAIS individuals have impaired neutrophil function. The proteome related to inflammation is predominantly inhibited in CAIS. Upregulation of IFN-β and IL-6 are reported in the blood of CAIS individuals. Leukocytes of CAIS individuals exhibit relative resistance to DNA damaging.
Paper chromatography is a technique that involves placing a small dot or line of sample solution onto a strip of chromatography paper. The paper is placed in a container with a shallow layer of solvent and sealed. As the solvent rises through the paper, it meets the sample mixture, which starts to travel up the paper with the solvent. This paper is made of cellulose, a polar substance, and the compounds within the mixture travel further if they are less polar. More polar substances bond with the cellulose paper more quickly, and therefore do not travel as far.
=== Drug design === A solvated ligand that binds the protein of interest is likely to exist as an equilibrium mixture of several conformers. Likewise the solvated protein also exists as several conformers in equilibrium. Formation of protein-ligand complex includes displacement of the solvent molecules that occupy the binding site of the ligand, to produce a solvated complex. Because this necessarily means that the interaction is entropically disfavored, highly favorable enthalpic contacts between the protein and the ligand must compensate for the entropic loss. The design of new ligands is usually based on the modification of known ligands for the target proteins. Proteases are enzymes that catalyze hydrolysis of a peptide bond. These proteins have evolved to recognize and bind the transition state of peptide hydrolysis reaction which is a tetrahedral intermediate. Therefore, the main protease inhibitors are tetrahedral intermediate mimics having an alcohol or a phosphate group. Examples are saquinavir, ritonavir, pepstatin, etc.
Sources: en.wikipedia.org
=== COVID-19 pandemic === In June 2020, following Novak Djokovic's Adria Tour, several players tested positive for COVID-19. Due to his possible exposure, Zverev announced on Twitter that he would be following self-isolation procedures after testing negative for the virus. However, one week later, Zverev was captured on video at a party in Monaco, prompting criticism from fellow tennis players Nick Kyrgios and Katie Boulter.
285: 483-488, 2001) Molecular Pathomechanisms and New Trends in Drug Research (editor and co-author CRC Press Taylor and Frances Group, 2003) Drug discovery in the kinase inhibitory field using the Nested Chemical Library (TM) technology (co-author, ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES 3: 543-551, 2005) Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death (co-author, CANCER RESEARCH 67:1602-1608, 2007) AXL is a potential target for therapeutic intervention in breast cancer progression (co-author, CANCER RESEARCH 68:1905-1915, 2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle (co-author, MOLECULAR CELL 31:438-448, 2008) Proteomics strategy for quantitative protein interaction profiling in cell extracts (co-author, NATURE METHODS 6: 741-744, 2009) Integrating molecular diagnostics into anticancer drug discovery (co-author NATURE REVIEWS DRUG DISCOVERY 9:(523-535, 2010) Development of a Cell Selective and Intrinsically Active Multikinase Inhibitor Bioconjugate (co-author, BIOCONJUGATE CHEMISTRY 22:540-545,2011) Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance BIOCHEMICAL PHARMACOLOGY 84: 260-267, 2012 Developing FGFR4 inhibitors as potential anticancer agents via in silico design, supported by in vitro and cellbased (co-author CURRENT MEDICINAL CHEMISTRY 20:1203-1217, 2013
Although the exact reason these proteins become targets of the immune system is not completely understood, they are thought to become exposed during inflammation or other changes within the cell. Once immune tolerance is lost, B lymphocytes produce anti-U1 RNP antibodies that recognize components of the U1 snRNP complex. While these antibodies are primarily used as biomarkers for autoimmune disease, studies continue to investigate whether they also contribute to inflammation and disease progression.
Sources: en.wikipedia.org
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.
It describes the share of the chromatographic signal belonging to the main peak, not the mass fraction of peptide in the vial. Water, counter-ions such as acetate or trifluoroacetate, and residual solvents account for part of the weight of a lyophilized lot. Peptide content by mass is a separate measurement and is often reported alongside purity.
Mass spectrometry is the primary check, because the measured mass can be compared with the expected value for the fifteen-residue chain. Sequence analysis or amino acid composition provides an independent confirmation. Purity testing alone does not establish identity, since a mixture of unrelated short peptides can still produce a clean-looking chromatogram.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.